psb205
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03986606)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06884982 | Phase 2 | Mar 13, 2025 | Nanjing Medical University |
| NCT05262413 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2022 | Qilu Pharmaceutical Co., Ltd. |
| NCT03986606 | Phase 1 | Jun 30, 2019 | Pharmaceutical Research Associates, Inc. (PRA), Sound Biologics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2019 |
| Qilu Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Sound Biologics | For profit | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1